Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction

被引:27
|
作者
Li, Chong [1 ]
Zhan, Changyou [2 ,3 ]
Zhao, Le [2 ,3 ]
Chen, Xishan [4 ,5 ]
Lu, Wei-Yue [4 ,5 ]
Lu, Wuyuan [2 ,3 ,4 ,5 ]
机构
[1] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400715, Peoples R China
[2] Univ Maryland Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[3] Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Minist Educ, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China
[5] Fudan Univ Sch Pharm, PLA, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Retro-inverso peptide; p53; MDM2; MDMX; D-Peptide; Apamin; Stingin; D-PEPTIDE INHIBITORS; P53; PATHWAY; AFFINITY; MDM2; ACTIVATION; DESIGN; ENANTIOMERS; MIMICRY;
D O I
10.1016/j.bmc.2013.04.039
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peptide retro-inverso isomerization is thought to be functionally neutral and has been widely used as a tool for designing proteolytically stable D-isomers to recapitulate biological activities of their parent L-peptides. Despite success in a wide range of applications, exceptions amply exist that clearly defy this rule of thumb when parent L-peptides adopt an a-helical conformation in their bound state. The detrimental energetic effect of retro-inverso isomerization of an a-helical L-peptide on its target protein binding has been estimated to be 3.0-3.4 kcal/mol. To better understand how the retro-inverso isomer of a structured protein works at the molecular level, we chemically synthesized and functionally characterized the retro-inverso isomer of a rationally designed miniature protein termed stingin of 18 amino acid residues, which adopts an N-terminal loop and a C-terminal alpha-helix stabilized by two intra-molecular disulfide bridges. Stingin emulated the transactivation peptide of the p53 tumor suppressor protein and bound with high affinity and via its C-terminal a-helix to MDM2 and MDMX-the two negative regulators of p53. We also prepared the retro isomer and D-enantiomer of stingin for comparative functional studies using fluorescence polarization and surface plasmon resonance techniques. We found that retro-inverso isomerization of L-stingin weakened its MDM2 binding by 720 fold (3.9 kcal/mol); while enantiomerization of L-stingin drastically reduced its binding to MDM2 by three orders of magnitude, sequence reversal completely abolished it. Our findings demonstrate the limitation of peptide retro-inverso isomerization in molecular mimicry and reinforce the notion that the strategy works poorly with biologically active a-helical peptides due to inherent differences at the secondary and tertiary structural levels between an L.-peptide and its retro-inverso isomer despite their similar side chain topologies at the primary structural level) (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4045 / 4050
页数:6
相关论文
共 50 条
  • [21] Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs
    Holzer, Philipp
    CHIMIA, 2017, 71 (10) : 716 - 721
  • [22] p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
    Nayak, Surendra Kumar
    Khatik, Gopal L.
    Narang, Rakesh
    Monga, Vikramdeep
    Chopra, Harish Kumar
    CURRENT CANCER DRUG TARGETS, 2018, 18 (08) : 749 - 772
  • [23] Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function
    Chen, D.
    Zhang, Z.
    Li, M.
    Wang, W.
    Li, Y.
    Rayburn, E. R.
    Hill, D. L.
    Wang, H.
    Zhang, R.
    ONCOGENE, 2007, 26 (35) : 5029 - 5037
  • [24] Hopf bifurcation analysis for a mathematical model of P53-Mdm2 interaction
    Neamtu, Mihaela
    Horhat, Raul Florin
    Opris, Dumitru
    INTERNATIONAL JOURNAL OF BIFURCATION AND CHAOS, 2008, 18 (01): : 275 - 283
  • [25] Possible oscillatory behavior in p53-mdm2 interaction computer simulation
    Mihalas, GI
    Simon, Z
    Balea, G
    Popa, E
    JOURNAL OF BIOLOGICAL SYSTEMS, 2000, 8 (01) : 21 - 29
  • [26] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
    Chène, P
    NATURE REVIEWS CANCER, 2003, 3 (02) : 102 - 109
  • [27] Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction
    Lemos, Agostinho
    Leao, Mariana
    Soares, Joana
    Palmeira, Andreia
    Pinto, Madalena
    Saraiva, Lucilia
    Sousa, Maria Emilia
    MEDICINAL RESEARCH REVIEWS, 2016, 36 (05) : 789 - 844
  • [28] Targeting the p53-MDM2 interaction: Synthesis of novel chlorofusin analogs
    Goffin, Sarah Anne
    Howell, Lesley Ann
    Searcey, Mark
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [29] Patented inhibitors of p53-Mdm2 interaction (2006-2008)
    Weber, Lutz
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (02) : 179 - 191
  • [30] In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor
    Vaupel, Andrea
    Holzer, Philipp
    Ferretti, Stephane
    Guagnano, Vito
    Kallen, Joerg
    Mah, Robert
    Masuya, Keiichi
    Ruetz, Stephan
    Rynn, Caroline
    Schlapbach, Achim
    Stachyra, Therese
    Stutz, Stefan
    Todorov, Milen
    Jeay, Sebastien
    Furet, Pascal
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (20) : 3404 - 3408